BridgeBio Pharma (BBIO) Minority Interest (2018 - 2026)

BridgeBio Pharma (BBIO) has 9 years of Minority Interest data on file, last reported at $10.4 million in Q1 2026.

• For the quarter ending Q1 2026, Minority Interest rose 4.84% year-over-year to $10.4 million; the trailing twelve-month figure through Mar 2026 stood at $10.4 million (up 4.84% YoY), and the FY2025 full-year result was $10.6 million, up 4.42% from the prior year.
• Minority Interest fell to $10.4 million in Q1 2026, from $10.6 million in the prior quarter.
• In the past five years, Minority Interest ranged from a high of $12.4 million in Q3 2023 to a low of $336000.0 in Q1 2022.
• A 5-year average of $10.4 million and a median of $10.9 million in 2024 frame the typical range for Minority Interest.
• Across the five-year window, Minority Interest slumped 73.56% in 2022 and jumped 3547.62% in 2023, its largest moves.
• Tracing BBIO's Minority Interest over 5 years: stood at $11.3 million in 2022, then decreased by 0.34% to $11.2 million in 2023, then decreased by 9.73% to $10.2 million in 2024, then grew by 4.42% to $10.6 million in 2025, then decreased by 1.51% to $10.4 million in 2026.
• Business Quant data shows BBIO's Minority Interest at $10.4 million in Q1 2026, $10.6 million in Q4 2025, and $10.3 million in Q3 2025.